» Articles » PMID: 37546557

Interaction Mechanisms Between Autophagy and Ferroptosis: Potential Role in Colorectal Cancer

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a common malignancy that has the second highest incidence and mortality rate. Although there are many personalized treatment options for CRC, the therapeutic effects are ultimately limited by drug resistance. Studies have aimed to block the initiation and progression of CRC by inducing cell death to overcome this obstacle. Substantial evidence has indicated that both autophagy and ferroptosis play important regulatory roles in CRC. Autophagy, a lysosome-dependent process by which cellular proteins and organelles are degraded, is the basic mechanism for maintaining cell homeostasis. The duality and complexity of autophagy in cancer therapy is a hot topic of discussion. Ferroptosis, a regulated cell death pathway, is associated with iron accumulation-induced lipid peroxidation. The activation of ferroptosis can suppress CRC proliferation, invasion and drug resistance. Furthermore, recent studies have suggested an interaction between autophagy and ferroptosis. Autophagy can selectively degrade certain cellular contents to provide raw materials for ferroptosis, ultimately achieving antitumor and anti-drug resistance. Therefore, exploring the interaction between autophagy and ferroptosis could reveal novel ideas for the treatment of CRC. In this review, we describe the mechanisms of autophagy and ferroptosis, focusing on their roles in CRC and the crosstalk between them.

Citing Articles

Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies.

Zhao F, Jiang X, Li Y, Huang T, Xiahou Z, Nie W Front Immunol. 2025; 15:1500153.

PMID: 39896800 PMC: 11782144. DOI: 10.3389/fimmu.2024.1500153.


CKS2 induces autophagy-mediated glutathione metabolic reprogramming to facilitate ferroptosis resistance in colon cancer.

Yang L, Fang C, Han J, Ren Y, Yang Z, Shen L Mol Med. 2024; 30(1):219.

PMID: 39548421 PMC: 11568617. DOI: 10.1186/s10020-024-00979-5.


Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics.

Rustandi T, Yumassik A, Ilahi F, Alfian R, Prihandiwati E, Susanto Y Front Pharmacol. 2024; 15:1428755.

PMID: 38994207 PMC: 11236599. DOI: 10.3389/fphar.2024.1428755.

References
1.
Chen J, Zhang J, Chen T, Bao S, Li J, Wei H . Xiaojianzhong decoction attenuates gastric mucosal injury by activating the p62/Keap1/Nrf2 signaling pathway to inhibit ferroptosis. Biomed Pharmacother. 2022; 155:113631. DOI: 10.1016/j.biopha.2022.113631. View

2.
Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J . AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System X Activity. Curr Biol. 2018; 28(15):2388-2399.e5. PMC: 6081251. DOI: 10.1016/j.cub.2018.05.094. View

3.
Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

4.
Miotto G, Rossetto M, Di Paolo M, Orian L, Venerando R, Roveri A . Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2019; 28:101328. PMC: 6812032. DOI: 10.1016/j.redox.2019.101328. View

5.
Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View